Welcome to our "One Minute Can Save a Life" video series where we will be sharing monthly our short FORCE videos that we hope will educate and inspire you. Please share with your friends, family and anyone who might be helped by viewing these life-saving messages.

This month we celebrate life's blessings.  Watch as Karen Kramer, FORCE Vice President of Marketing, recounts her unique story and reminds us that men can pass along BRCA mutations too!

"One Minute Can Save a Life" Video Series Testing Positive - and Thankful

Ovarian Cancer Treatment Studies

• SOLO2 is a Phase III, randomized, double blind, placebo controlled, multicenter study of olaparib maintenance monotherapy in platinum sensitive relapsed BRCA mutated ovarian cancer patients in complete or partial response after platinum based chemotherapy.
• ARIEL3 is a Phase 3 trial studying rucaparib as switch maintenance following platinum-based chemotherapy in patients with platinum-sensitive, high-grade serous or endometrioid ovarian, fallopian tube, or PPC cancer.  A BRCA mutation is not required for entry into this study.
• NOVA is a maintenance trial for women with ovarian cancer to find out if niraparib (a PARP inhibitor) can help delay worsening in patients who had a good response to previous treatment with a platinum-type chemotherapy.

Breast Cancer Treatment Studies

• OlympiAD is a phase III study comparing how olaparib (a PARP inhibitor) works compared to standard chemotherapy in  patients with HER2 negative metastatic breast cancer who have a BRCA1 or BRCA2 mutation.  Patients will be randomized 2 to 1, so patients will be twice as likely to receive olaparib than standard chemotherapy. Patients who may be eligible for the study but do not know their BRCA mutation status will be tested at no expense. 

• BROCADE is a phase II clinical trial for people with advanced hereditary breast cancer. 

• BRAVO is a trial for men and women who have HER2 negative, BRCA mutation positive breast cancer that progressed after prior treatment. BRAVO will compare niraparib (a PARP inhibitor) with standard chemotherapy.  

Pancreatic Cancer Treatment Studies

• RUCAPANC is a Phase 2 study of the oral PARP inhibitor rucaparib in BRCA-mutant locally advanced or metastatic pancreatic cancer.

Visit our research page for other HBOC studies 

Take Our Survey on Menopause Management After BSO 

If you are high risk for ovarian cancer and have had risk-reducing surgery to remove your ovaries, please consider taking our ABOUT Network anonymous survey on decision-making around menopause management.   

Visit Team FORCE

Rhonda discovered her interest in genetics in a junior high school science class. Thankfully for the hereditary breast and ovarian cancer community, she decided on a career in genetic counseling.  Rhonda shares her knowledge with those in our community via the FORCE Helpline. She provides information and resources that make the journey just a little easier.  But, Rhonda feels as if the answered questions she provides are dwarfed in comparison to the wisdom and inspiration she has received from working with FORCE families. If you are interested in becoming a volunteer and joining the fight against hereditary breast and ovarian cancer, in whatever way works for you, please fill out our volunteer survey.